13F reference period
Q2 2026
Security Snapshot
AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (AGIO) Institutional Ownership
CUSIP: 00847X104
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
235
Shares (Excl. Options)
66M
Full value: 66,003,474 · shares · 30 Jun 2026Price
$37.11
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Symbol
- AGIO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 66,003,474
- Total 13F value
- $2,451,840,378
- Portfolio coverage rank
- 0.01%
- Share change
- +2,984,814
- Value change
- +$129,540,497
- Number of holders
- 235
- Shares outstanding
- 59,771,717
- SEC-reported price per share
- $33.25
- Insider filing price
- $33.25
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 00847X104.
- 235 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 232 to 235 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$2.12B
Full value: $2,120,792,628 · USD · 31 Mar 2026.$2.45B
Full value: $2,451,840,378 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 235 institutions filings for Q2 2026.
Security key
00847X104
13F reference period
Q2 2026
13F holders
235
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
AGIO full holder history
AGIOS PHARMACEUTICALS, INC. SEC filings
AGIOS PHARMACEUTICALS, INC. company facts
AGIOS PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00847X104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
AGIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.9% | $239,950,570 | 5,917,400 | Farallon Capital Management, L.L.C. | 30 Jun 2026 | |||
| Farallon Capital Partners, L.P. | 8.8% | -11% | $146,117,182 | -$14,583,696 | 5,159,505 | -9.1% | Dapice Joshua J. | 31 Dec 2025 |
| BlackRock, Inc. | 7.8% | $150,100,362 | 4,513,170 | BlackRock, Inc. | 30 Jun 2025 | |||
| STATE STREET CORP | 5.3% | $88,022,666 | 3,108,145 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.3% | $104,472,757 | 3,088,169 | Vanguard Capital Management | 31 Mar 2026 | |||
| D. E. SHAW & CO, L.P. | 5.1% | $85,832,737 | 3,034,031 | D. E. Shaw & Co., L.P. | 25 Jun 2026 | |||
| Lynx1 Capital Management LP | 5.1% | $105,819,749 | 3,013,949 | Lynx1 Capital Management LP | 29 Apr 2026 | |||
| Paradigm Biocapital Advisors LP | 4.9% | -6% | $115,344,498 | -$6,198,499 | 2,873,555 | -5.1% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| ARMISTICE CAPITAL, LLC | 4.6% | -13% | $95,358,760 | -$11,235,200 | 2,716,000 | -11% | Armistice Capital, LLC | 31 Mar 2026 |
As of 30 Jun 2026,
235
institutional investors reported holding
shares of
AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (AGIO).
This represents
110%
of the company’s total
outstanding shares.
66M
Full value: 66,003,474 · shares · 30 Jun 202659.77M
Full value: 59,771,717 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
84%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 6,455,997 | +12% | 0% | $239,582,050 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.9% | 5,917,400 | +4.1% | 1.3% | $219,594,714 |
| STATE STREET CORP | 5.9% | 3,533,633 | +5% | 0% | $131,144,972 |
| Lynx1 Capital Management LP | 5.7% | 3,408,937 | +31% | 15% | $126,505,652 |
| D. E. Shaw & Co., Inc. | 5.2% | 3,107,005 | +16% | 0.07% | $115,300,956 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.8% | 2,898,197 | +11% | 0% | $107,552,091 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 2,681,845 | +1.9% | 0% | $99,523,268 |
| ARMISTICE CAPITAL, LLC | 4% | 2,400,000 | -12% | 2.5% | $89,064,000 |
| Erste Asset Management GmbH | 3.6% | 2,154,900 | -20% | 0.64% | $81,972,396 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.5% | 2,110,809 | +41% | 0.12% | $78,332,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 1,574,268 | +7.2% | 0% | $58,433,490 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.3% | 1,375,558 | +2.3% | 0.05% | $51,046,957 |
| ADAR1 Capital Management, LLC | 2.2% | 1,288,053 | +816% | 2.3% | $47,799,647 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2.1% | 1,280,044 | -19% | 0.05% | $47,502,433 |
| DIMENSIONAL FUND ADVISORS LP | 2.1% | 1,248,738 | +8.4% | 0.01% | $46,345,467 |
| GW&K Investment Management, LLC | 2% | 1,206,615 | -0.68% | 0.35% | $44,777,000 |
| GOLDMAN SACHS GROUP INC | 1.9% | 1,150,932 | +43% | 0% | $42,711,087 |
| UBS Group AG | 1.6% | 985,831 | +644% | 0.01% | $36,584,189 |
| MORGAN STANLEY | 1.6% | 963,255 | -0.44% | 0% | $35,746,419 |
| Nuveen, LLC | 1.5% | 873,560 | +21% | 0.01% | $32,417,811 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.4% | 810,530 | +224% | 0.01% | $30,078,768 |
| Foresite Capital Management VI LLC | 1.3% | 785,000 | +50% | 4.5% | $29,131,350 |
| CITADEL ADVISORS LLC | 1.2% | 732,687 | +18% | 0.02% | $27,190,015 |
| AQR CAPITAL MANAGEMENT LLC | 1.1% | 684,340 | +1780% | 0.01% | $25,395,858 |
| Parkman Healthcare Partners LLC | 1.1% | 669,046 | +66% | 2.5% | $24,828,297 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,128,793 | $70,756,498 | +$62,378,716 | $33.25 | 32 |
| 2026 Q2 | 66,003,474 | $2,451,840,378 | +$129,540,497 | $37.11 | 235 |
| 2026 Q1 | 63,077,301 | $2,120,792,628 | +$71,838,431 | $33.83 | 232 |
| 2025 Q4 | 61,265,073 | $1,667,804,671 | -$303,649,463 | $27.22 | 237 |
| 2025 Q3 | 63,487,439 | $2,545,616,686 | +$81,769,351 | $40.14 | 216 |
| 2025 Q2 | 61,683,672 | $2,051,725,997 | +$65,237,829 | $33.26 | 211 |
| 2025 Q1 | 59,963,279 | $1,757,322,194 | -$10,187,060 | $29.30 | 216 |
| 2024 Q4 | 59,832,436 | $1,966,429,716 | +$37,958,970 | $32.86 | 221 |
| 2024 Q3 | 58,096,571 | $2,582,267,784 | -$8,181,474 | $44.43 | 204 |
| 2024 Q2 | 58,132,966 | $2,506,935,894 | -$125,225,015 | $43.12 | 203 |
| 2024 Q1 | 61,946,791 | $1,811,267,450 | +$89,235,062 | $29.24 | 183 |
| 2023 Q4 | 59,884,422 | $1,333,701,271 | +$15,853,345 | $22.27 | 167 |
| 2023 Q3 | 59,110,077 | $1,463,036,585 | -$8,921,651 | $24.75 | 142 |
| 2023 Q2 | 59,366,269 | $1,679,785,246 | +$16,420,594 | $28.32 | 150 |
| 2023 Q1 | 58,996,438 | $1,355,139,176 | -$9,985,145 | $22.97 | 161 |
| 2022 Q4 | 59,442,573 | $1,669,125,079 | +$45,133,345 | $28.08 | 156 |
| 2022 Q3 | 57,972,960 | $1,639,524,356 | -$46,396,034 | $28.28 | 155 |
| 2022 Q2 | 59,017,906 | $1,308,562,484 | -$21,425,021 | $22.17 | 143 |
| 2022 Q1 | 59,895,743 | $1,743,443,247 | +$19,219,573 | $29.11 | 146 |
| 2021 Q4 | 59,210,281 | $1,947,305,194 | -$73,787,635 | $32.87 | 148 |
| 2021 Q3 | 60,890,488 | $2,810,077,563 | -$244,072,957 | $46.15 | 157 |
| 2021 Q2 | 65,926,694 | $3,632,531,095 | +$51,380,893 | $55.11 | 179 |
| 2021 Q1 | 65,233,267 | $3,366,007,585 | +$56,136,770 | $51.64 | 168 |
| 2020 Q4 | 64,981,734 | $2,817,090,446 | -$19,419,372 | $43.33 | 189 |
| 2020 Q3 | 65,869,834 | $2,304,359,620 | -$101,763,130 | $35.00 | 206 |